The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
Saved in:
| Title: | The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective. |
|---|---|
| Authors: | Perry WL 3rd; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. bperry@lilly.com, Weitzman A |
| Source: | Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2005 Mar; Vol. 3 (3), pp. 199-202, 237-8. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Millennium Medical Pub Country of Publication: United States NLM ID: 101167661 Publication Model: Print Cited Medium: Internet ISSN: 1543-0790 (Print) Linking ISSN: 15430790 NLM ISO Abbreviation: Clin Adv Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
